The table below shows Arcutis Biotherapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$5.63M
-$112.16M
-$247.06M
-$257.71M
-$174.63M
-$113.03M
Capital expenditure
$686.00K
$143.00K
$428.00K
$333.00K
$995.00K
$321.00K
Investing cash flow
-$30.25M
$28.82M
$180.23M
-$87.20M
-$75.95M
-$181.82M
Dividends paid
-
-
-
-
ARQT operating cash flow (10-K history)
Arcutis Biotherapeutics, Inc. reported operating cash flow of -$5.63M for fiscal year 2025. That is up 95.0% from -$112.16M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$14.09M (FY 2018) to -$5.63M. Figures come from the company's audited annual reports as filed with the SEC.